🔴 Femasys is trading 6.27% down in after-hours trading amid apparent profit-taking after FDA pathway approval

Femasys is trading at $2.54, down 6.27%, with the after-hours decline appearing to reflect profit-taking after the FDA approved a modular PMA pathway for FemBloc.

• Shares rallied sharply after the regulatory milestone, then surrendered most gains during regular trading.
• The stock closed at $2.71 on August 19, 2026.
• The decline does not appear tied to a newly reported negative announcement.